Trials / Completed
CompletedNCT00821444
Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules
Phase 1 Study Of Ziprasidone Pharmacokinetics Of Reduced Food Effect Formulation B16 Under Fed And Fasting Conditions Compared To Commercial Geodon Capsules Under Fed Conditions In Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Commercial ziprasidone capsules show a large increase in bioavailability with food. The formulation tested in this study aims to reduce or eliminate that increase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ziprasidone | 40 mg capsule, single dose x 3 |
| DRUG | B16 Fasted | 40 mg tablet, single dose X 3 |
| DRUG | B16 Fed | 40 mg tablet, single dose X 3 |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2009-01-13
- Last updated
- 2021-02-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00821444. Inclusion in this directory is not an endorsement.